SAB BIO Highlights Data in Multiple Presentations at EASD
SAB BIO Highlights Data in Multiple Presentations at EASD GlobeNewswire September 19, 2025 -As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study- -Data in multiple SAB presentations and INNODIA's MELD-ATG […]